Intec Pharma

Tel Aviv Stock Exchange: NTEC

Market CapNIS495.1m

Last Close NIS14.9

Intec Pharma is a drug delivery company that has developed the accordion pill, a novel gastroretentive controlled release formulation. The company is currently using this technology to develop AP-CDLD for Parkinson’s in Phase III and AP-ZP for insomnia in Phase II.

More Intec Pharma content >

Investment summary

Edison Investment Research is terminating coverage on Intec Pharma (NTEC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2016A 0.0 (14.5) (13.4) (116.72) N/A N/A
2017A 0.0 (30.1) (29.1) (164.74) N/A N/A
2018E 0.0 (31.2) (29.5) (93.22) N/A N/A
2019E 0.0 (25.0) (22.8) (67.94) N/A N/A
Content on Intec Pharma
Intec Pharma – Termination of coverage
Healthcare | Termination | 4 January 2019
Intec Pharma – Getting closer to data
Healthcare | Update | 14 August 2018
View more
Share price graph
Balance sheet
Forecast net cash (US$m) 57.2
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 0.0 (10.4) (47.9)
Relative* 4.7 (12.9) (52.4)
52-week high/low NIS29.6/NIS14.3
*% relative to local index
Key management
John W Kozarich Chairman
Jeffrey A Meckler CEO
Nir Sassi CFO